首页 > 市场调查报告书 > 製药

糖尿病

市场调查报告书

商品编码

1673934

人类胰岛素製剂市场按产品类型、应用和地区划分

Human Insulin Drug Market, By Product Type, By Type, By Application, By Geography

出版日期: 2025年02月20日 | 出版商:

Coherent Market Insights | 英文 165 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2025 年全球人类胰岛素製剂市场规模估计为 570.4 亿美元，预计到 2032 年将达到 1,023.5 亿美元，2025 年至 2032 年的复合年增长率为 8.7%。

报告范围		报告详细信息
基准年	2024	2025 年市场规模	570.4亿美元
效能资料	2020-2024	预测期	2025-2032
预测期：2025 年至 2032 年复合年增长率	8.70％	2032 年金额预测	1023.5亿美元

数字。 2025 年人类胰岛素製剂市场占有率（按地区划分）

由于全球糖尿病盛行率不断上升，过去几年全球人类胰岛素製剂市场一直稳定成长。人类胰岛素製剂是常规人类胰岛素的生物合成版本，用于治疗和控製糖尿病。根据国际糖尿病联盟发布的资料，2020年全球约有4.63亿成年人患有糖尿病，预计2045年将上升至7亿。糖尿病患者数量的增加、人们对胰岛素治疗认识的提高以及胰岛素笔和胰岛素帮浦等创新胰岛素输送系统的推出，预计将推动全球对人类胰岛素製剂的需求。

市场动态

全球人类胰岛素製剂市场的成长主要受到肥胖、久坐的生活方式、人口老化和遗传因素导致的糖尿病盛行率不断上升的推动。根据世界卫生组织统计，糖尿病是主要死亡原因之一，估计每年有150万人死于糖尿病。人们对胰岛素治疗的认识不断提高，以及胰岛素帮浦和胰岛素笔等各种创新的胰岛素给药方式，可能会推动市场成长。然而，人类胰岛素製剂的高成本可能会阻碍市场的成长。生物相似药人类胰岛素製剂的开发为市场参与企业带来了丰厚的成长机会。

研究的主要特点

本报告对全球人类胰岛素製剂市场进行了详细分析，并以 2024 年为基准年，给出了预测期（2025-2032 年）的市场规模（十亿美元）和年复合成长率（CAGR%）。
它还强调了各个领域的潜在收益成长机会，并说明了该市场的引人注目的投资提案矩阵。
它还提供了对市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
全球人类胰岛素製剂市场的主要企业已根据公司亮点、产品系列、关键亮点、财务绩效和策略等参数进行了分析。
主要企业包括赛诺菲、诺和诺德 A/S、Biocon Limited、辉瑞公司、礼来公司、Wockhardt Ltd.、SEDICO、Exir、Aventis、默克公司、Julphar、GLENMARK PHARMACEUTICALS LTD.、勃林格格翰国际有限公司和殷迈兰公司。
本报告的见解将使负责人和企业经营团队能够就未来产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。
全球人类胰岛素製剂市场迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
可以透过分析全球人类胰岛素製剂市场所使用的各种策略矩阵来促进相关人员的决策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 57.04 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	8.70%	2032 Value Projection:	USD 102.35 Bn

Global human insulin drug market has been witnessing steady growth over the past few years, owing to increasing prevalence of diabetes across the world. Human insulin drugs are biosynthetically manufactured versions of regular human insulin that is used for the treatment and management of diabetes. According to the data published by the International Diabetes Federation, approximately 463 million adults lived with diabetes in 2020 and the number is expected to rise to 700 million by 2045. Growing diabetic population, rising awareness about insulin therapy, introduction of innovative insulin drug delivery systems such as insulin pens and pumps are expected to boost demand for human insulin drugs globally.

Market Dynamics:

Global human insulin drug market growth is primarily driven by growing incidence of diabetes owing to obesity, sedentary lifestyle, aging population, and genetic factors. According to WHO, diabetes is one of the major causes of death with an estimated 1.5 million deaths caused by diabetes every year. Rising awareness about insulin therapy and various innovative drug delivery options for insulin administration such as insulin pumps and pens can drive the market growth. However, high cost of human insulin drugs can hamper the market growth. The development of biosimilar human insulin drugs provides lucrative growth opportunities for players in the market.

Key Features of the Study:

This report provides an in-depth analysis of the global human insulin drug market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global human insulin drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this includes Sanofi, Novo Nordisk A/S, Biocon Limited, Pfizer Inc., Eli Lilly and Company, Wockhardt Ltd., SEDICO, Exir, Aventis , Merck & Co., Inc., Julphar, GLENMARK PHARMACEUTICALS LTD., Boehringer Ingelheim International GmbH, Mylan N.V.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global human insulin drug market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global human insulin drug market

Detailed Segmentation-

By Product Type:
- Human Insulin
- Basal Insulin
- Bolus Insulin
- Insulin Combinations
- Biosimilar Insulins
By Type:
- Short Acting
- Long Acting
BY Application:
- Type 1 Diabetes
- Type 2 Diabetes
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Sanofi
- Novo Nordisk A/S
- Biocon Limited
- Pfizer Inc.
- Eli Lilly and Company
- Wockhardt Ltd.
- SEDICO
- Exir
- Aventis
- Merck & Co., Inc.
- Julphar
- GLENMARK PHARMACEUTICALS LTD.
- Boehringer Ingelheim International GmbH
- Mylan N.V.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By Type
- Market Snapshot, By Application
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Market Trends
Key Developments
Regulatory Scenario
Manufacturer Revenue
Acquisitions and Partnerships Scenario
Product Launches/Approvals
Funding and Investments
PEST Analysis
Porter's Analysis

4. Global Human Insulin Drug Market - Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the Market

5. Global Human Insulin Drug Market, By Product Type, 2020 - 2032, (USD Bn)

Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Human Insulin
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Basal Insulin
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Bolus Insulin
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Insulin Combinations
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Biosimilar Insulins
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Human Insulin Drug Market, By Type, 2020 - 2032, (USD Bn)

Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Short Acting
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Long Acting
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Human Insulin Drug Market, By Application, 2020 - 2032, (USD Bn)

Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Type 1 Diabetes
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Type 2 Diabetes
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Human Insulin Drug Market, By Region, 2020 - 2032, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021-2032
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Forecast, and Y-o-Y Growth, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Company Profiles
- Sanofi*
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Novo Nordisk A/S
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Biocon Limited
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Pfizer Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Eli Lilly and Company
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Wockhardt Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- SEDICO
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Exir
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Aventis
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Merck & Co., Inc.
- Julphar
- GLENMARK PHARMACEUTICALS LTD.
- Boehringer Ingelheim International GmbH.
- Mylan N.V.

10. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

11. References and Research Methodology

References
Research Methodology
About us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

人类胰岛素製剂市场按产品类型、应用和地区划分